| Jul 8 |
Xeris Biopharma Announces CEO Succession Plan
|
| Jul 3 |
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
| Jun 6 |
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit
|
| Jun 3 |
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
|
| May 30 |
Xeris stock jumps 14% on Phase 2 data for injected levothyroxine
|
| May 30 |
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
|
| May 30 |
Xeris to Participate in the Jefferies Global Healthcare Conference
|
